Urology
Volume 72, Issue 1 , Pages 205-213 , July 2008

Elevated Epithelial Expression of Interleukin-8 Correlates with Myofibroblast Reactive Stroma in Benign Prostatic Hyperplasia

Received 15 August 2006 ,Accepted 12 November 2007.

References 

  1. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15:340–345
  2. Price H, McNeal JE, Stamey TA. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol. 1990;21:578–585
  3. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479
  4. McNeal J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am. 1990;17:477–486
  5. Rowley DR. What might a stromal response mean to prostate cancer progression?. Cancer Metast Rev. 1998;17:411–419
  6. Tuxhorn JA, Ayala GE, Smith MJ, et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8:2912–2923
  7. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–1659
  8. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202–1216
  9. Black JL, Burgess JK, Johnson PR. Airway smooth muscle—its relationship to the extracellular matrix. Respir Physiol Neurobiol. 2003;137:339–346
  10. Johnson PR, Burgess JK. Airway smooth muscle and fibroblasts in the pathogenesis of asthma. Curr Allergy Asthma Rep. 2004;4:102–108
  11. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol. 2001;159:1465–1475
  12. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583–594
  13. Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83:1131–1146
  14. Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 2001;159:139–147
  15. Castro P, Xia C, Gomez L, et al. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate. 2004;60:153–159
  16. Giri D, Ittmann M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 2000;157:249–255
  17. Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51:524–533
  18. Konig JE, Senge T, Allhoff EP, et al. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58:121–129
  19. Rosenkilde MM, Schwartz TW. The chemokine system—a major regulator of angiogenesis in health and disease. APMIS. 2004;112:481–495
  20. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003;9:4792–4801
  21. McNeal JE. Normal histology of the prostate. Am J Surg Pathol. 1988;12:619–633
  22. Gerdes MJ, Larsen M, Dang TD, et al. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate. 2004;58:299–307
  23. Hsia HC, Schwarzbauer JE. Meet the tenascins: multifunctional and mysterious. J Biol Chem. 2005;280:26641–26644
  24. Mori L, Bellini A, Stacey MA, et al. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res. 2005;304:81–90
  25. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol. 2001;166:2472–2483

 J. A. Tuxhorn is currently at Wyle, 1290 Hercules Drive, Houston, TX 77058 and her contribution to this work occurred while she was a student at Baylor College of Medicine; this study was not sponsored by Wyle.

 This study was supported by National Institutes of Health Training grant 5-T32-HD07165, National Institutes of Health grants RO1-CA058093, RO1-DK045909, and UO1-CA84296.

PII: S0090-4295(07)02466-1

doi: 10.1016/j.urology.2007.11.083

Urology
Volume 72, Issue 1 , Pages 205-213 , July 2008

Article Tools

* Image Usage & Resolution